{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012769","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.486899+00:00","generated_at":"2026-05-17T07:42:04.379665+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"MAIA presents Phase 2 THIO-101 poster at WCLC showing PFS improvement in advanced NSCLC","bullets":["Poster titled 'Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS' presented at 2025 WCLC on Sept 7, 2025.","Data from Phase 2 THIO-101 trial evaluating THIO + cemiplimab in advanced NSCLC patients who failed ≥2 prior therapies.","Specific efficacy numbers (e.g., median PFS, response rates) not disclosed in the filing; poster available on company website Sept 8.","No safety or additional endpoints described in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012769","json":"https://secwatch.observer/filing/0001493152-25-012769.json","markdown":"https://secwatch.observer/filing/0001493152-25-012769.md","text":"https://secwatch.observer/filing/0001493152-25-012769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225012769/0001493152-25-012769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225012769/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:42:04.379665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}